Cargando…
Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations
The first oral drug for the treatment of COVID-19, Paxlovid, has been authorized; however, nirmatrelvir, a major component of the drug, is reported to be associated with some side effects. Moreover, the appearance of many novel variants raises concerns about drug resistance, and designing new potent...
Autores principales: | Tam, Nguyen Minh, Nguyen, Trung Hai, Pham, Minh Quan, Hong, Nam Dao, Tung, Nguyen Thanh, Vu, Van V., Quang, Duong Tuan, Ngo, Son Tung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233213/ https://www.ncbi.nlm.nih.gov/pubmed/37295158 http://dx.doi.org/10.1016/j.jmgm.2023.108535 |
Ejemplares similares
-
Binding of inhibitors to the monomeric and dimeric SARS-CoV-2 Mpro
por: Tam, Nguyen Minh, et al.
Publicado: (2021) -
Searching and designing potential inhibitors for SARS-CoV-2 Mpro from natural sources using atomistic and deep-learning calculations
por: Tam, Nguyen Minh, et al.
Publicado: (2021) -
Unbinding ligands from SARS-CoV-2 Mpro via umbrella sampling simulations
por: Tam, Nguyen Minh, et al.
Publicado: (2022) -
Potential inhibitors for SARS-CoV-2 Mpro from marine compounds
por: Tam, Nguyen Minh, et al.
Publicado: (2021) -
DeepFrag: An Open-Source Browser App for Deep-Learning
Lead Optimization
por: Green, Harrison, et al.
Publicado: (2021)